Friday 13 Jun, 2025 08:10 AM
Site map | Locate Us | Login
   SG Mart forays into renewable energy sector with launch of APL Apollo SunSteel    Maithan Alloys acquires minority stake in GAIL (India) for Rs 12 cr    Kay Cee Energy & Infra hits the roof on securing Rs 28 cr transmission order from RVPN    C.E. Info Systems Ltd leads losers in 'A' group    C E Info Systems slumps after block deal    Ashoka Buildcon tumbles as GST notice triggers search & seizure operation    Cinevista Ltd leads losers in 'B' group    Happiest Minds appoints Anand Balakrishnan as chief financial officer    Crisil Ratings reaffirms ratings of Ratnamani Metals at 'AA/A1+' with 'stable' outlook    Volumes spurt at RHI Magnesita India Ltd counter    NTPC's North Karanpura project completes trial operations of unit-3    Dr Reddys Laboratories Ltd up for third consecutive session    Ipca Laboratories Ltd soars 1.25%, Gains for third straight session    Oil & Natural Gas Corpn Ltd spurts 0.72%, rises for fifth straight session    Oil India Ltd spurts 1.57%, gains for five straight sessions 
Saravan Stocks
       
Hot Pursuit
Scrips, which has significant changes during the market hours.
Biocon jumps as Bengaluru unit gets VAI status from USFDA
24-Dec-24   15:42 Hrs IST

The EIR is based on a surveillance inspection conducted by the United States Food and Drug Administration (USFDA) from the 16th to 20th of September 2024.

Meanwhile, the pharma company and Zentiva, its European partner, received a de-centralized procedure (DCP) approval for its complex formulation, Liraglutide, in the European Union (EU).

The approval is for the generic versions of Victoza to treat type-2 diabetes and Saxenda used in the treatment of weight management.

Biocon is an innovation-led global biopharmaceuticals company, engaged in the production of therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as Generic Formulations in the US, Europe & key emerging markets. It also has a pipeline of promising novel assets in immunotherapy under development.

The company reported a consolidated net loss of Rs 16 crore in Q2 FY25 as against a net profit of Rs 126 crore in Q2 FY24. Revenue from operations rose by 4% YoY to Rs 3,590 crore during the quarter.

Powered by Capital Market - Live News
   Attention Investors : Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day........issued in the interest of investors.
   Attention Investors : Prevent unauthorised transactions in your account Update your mobile numbers/email IDs with your stock brokers / Depository Participant. Receive information of your transactions directly from Exchange / Depositories on your mobile / email at the end of the day .... Issued in the interest of Investors.
   Attention Investors : KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
   Attention Investors : No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
Email ID: info@ssplwealth.com       Customers grievances : grievances@ssplwealth.com     Compliance officer : Mr.R Udayakumar , compliance@ssplwealth.com,  Mobile No: 7305522205
Investor Charter | Annual Return | Account Closure | RE-KYC | Disclaimer | Feed Back | Privacy Policy | Policies & Procedures | Rights & Obligations-English | (Rights & Obligations, Risk Disclosure Document, Do's & Don't's) in Vernacular Language | Anti Money Laundering Policy | E-Voting | CSR | Voluntary Freezing / Blocking | Policy GTC | Policy On Inactive Trading Accounts | Risk Disclosure Hit Count : 41898650
Useful Links : NSE | BSE | MCX | NSDL | CDSL | SEBI | RBI | ATTENTION INVESTOR| SMART ODR
SEBI Regn.Nos : NSE/BSE-INZ000192638 | CDSL : IN-DP-262-2016
Member IDs : NSE : 11221 | BSE : 6292 | CDSL : 12045000 | MCX : 56990 | AMFI Regn.No : 2662
Designed , Developed & Content provided by CMOTS INFOTECH.(ISO 9001:2015 certified) © Copyright 2011 All Rights Reserved. SSPL Securities Private Limited